Ligand Pharmaceuticals
LGND
197 hedge funds and large institutions have $1.33B invested in Ligand Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 60 increasing their positions, 76 reducing their positions, and 24 closing their positions.
464% more call options, than puts
Call options by funds: $4.73M | Put options by funds: $839K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5% less funds holding
Funds holding: 208 → 197 (-11)
7.31% less ownership
Funds ownership: 148.76% → 141.45% (-7.3%)
20% less capital invested
Capital invested by funds: $1.67B → $1.33B (-$341M)
21% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 76
29% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$8.51M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.88M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$5.29M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$4.24M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$47.1M |
| 2 |
SCM
Snyder Capital Management
San Francisco,
California
|
-$16.9M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$7.55M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.51M |
| 5 |
Millennium Management
New York
|
-$4.69M |
LGND Hedge Fund Activity: Q2 2022 in Review
197 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2022, worth a combined $1.33B — down 20% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LGND and 17 opened new positions — a net loss of 7 holders — while 76 trimmed existing stakes and 60 added.
The largest buyer was Aberdeen Group, adding an estimated $8.51M. The largest seller was William Blair Investment Management, cutting an estimated $47.1M.
- 197 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2022, down from 208 in Q1 2022.
- Funds reported $1.33B of Ligand Pharmaceuticals stock for Q2 2022, down 20% quarter-over-quarter.
- 17 funds opened new Ligand Pharmaceuticals positions in Q2 2022 and 24 closed out, a net change of -7 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2022 was Aberdeen Group, an estimated $8.51M added.
- The largest Ligand Pharmaceuticals seller in Q2 2022 was William Blair Investment Management, an estimated $47.1M sold.
Based on aggregated 13F filings for Q2 2022.